Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose
复制标题
DOI：
10.1016/j.lungcan.2012.09.018
复制
发表时间：
2013-01-01
期刊：
影响因子：
5.3
通讯作者：
Chen, Haiquan
中科院分区：
文献类型：
--
作者：
Li, Hang;Pan, Yunjian;Chen, Haiquan
目的：我们进行了这项分析，以揭示六个明确的致癌驱动突变与吸烟者肺腺癌的临床和病理特征之间的关联。方法：对上海市肿瘤防治中心230例手术切除的吸烟者肺腺癌（吸烟≥ 100支）进行EGFR、KRAS、BRAF、HER 2、EML 4-ALK和PIK 3CA基因突变检测。结果：在230例吸烟者中，我们检测到100例（43.5%）EGFR突变，38例（16.5%）KRAS突变，8例（3.5%）PIK 3CA突变，7例（3.0%）BRAF突变和7例（3.0%）EML 4-ALK融合。未发现HER 2突变，诊断时吸烟剂量≥ 60岁的患者EGFR突变发生率显著较高（p = 0.018）。吸烟剂量>20包-年和年龄
Purpose: We performed this analysis to reveal the association between six well-identified oncogenic driver mutations and clinical and pathological features in lung adenocarcinomas from smokers. It may have the potentiality to optimize existing treatment strategies and clinical trial design.Methods: In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA. Further we compared the mutation frequency with sex, age at diagnosis, stage, differentiation, smoking dose, and histological subtype.Results: Among 230 smokers, we detected 100 (43.5%) EGFR mutations, 38 (16.5%) KRAS mutations, 8 (3.5%) PIK3CA mutations, 7 (3.0%) BRAF mutations and 7 (3.0%) EML4-ALK fusions. No HER2 mutation was found. EGFR mutations occurred at a significantly higher frequency in patients with smoking dose = 60 years old at diagnosis (p = 0.018). Smoking dose >20 pack-years and age